Good Evening Reader,
Pull up (NASDAQ: SILO) tomorrow. Read below...
--
Silo Pharma, Inc.
Silo Pharma, Inc. (NASDAQ: SILO) is committed to developing innovative therapies for underserved conditions including Alzheimer’s disease, Fibromyalgia, and Stress-Induced Psychiatric Disorders. Through collaborations with leading academic institutions, Silo has licensed cutting-edge therapeutics designed to pursue the more efficient FDA 505(b)(2) regulatory pathway — a strategy that can lower costs, shorten development timelines, and accelerate patient access to much-needed treatments.
Why Investors Are Paying Attention:
Silo Pharma represents a rare blend of biopharma innovation and digital asset exposure, giving investors access to both a growing therapeutic pipeline and a crypto treasury management platform. With a lean structure, strategic partnerships, and advancing clinical programs, SILO is positioning itself for major catalysts in the months ahead.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on novel therapeutics targeting CNS disorders, stress-related conditions, and chronic pain.
Its key pipeline assets include:
● SPC-15 – an intranasal therapy for PTSD and stress-related disorders, licensed from Columbia University.
● SPC-26 – targeting fibromyalgia and chronic pain.
● SPC-14 – a preclinical candidate addressing Alzheimer’s disease.
The company’s research collaborations with top-tier universities and research institutions support its mission to bring transformative, science-driven solutions to patients with few available treatment options. Silo continues to strengthen its intellectual property portfolio, secure international patents, and advance multiple preclinical programs through the 505(b)(2) FDA pathway — a route designed to leverage existing safety data, reducing both cost and time to approval.
Recent & Notable Catalysts:
● Strategic Financing Completed Closed a registered direct offering of 2,857,143 shares at $0.875 per share, alongside private placement warrants at $0.75 per share — providing capital to advance its clinical and digital initiatives.
● Crypto Treasury Expansion Entered a strategic agreement with Fireblocks, a global leader in institutional digital asset custody and settlement, to build an institutional-grade crypto treasury platform.
● Global Patent Strengthening Received new patent grants from Japan and Australia protecting its SPC-15 PTSD therapy, expanding its international IP footprint.
● Preclinical Success in Alzheimer’s Research Published positive results for SPC-14 in Alzheimer’s Research & Therapy Journal, demonstrating improved cognitive function in animal models.
● Positive Safety Data for SPC-15 Completed a 7-day large animal safety study showing strong tolerability and safety for SPC-15’s intranasal delivery — supporting its FDA pathway toward clinical trials.
● Upcoming IND Submission Silo expects to complete final preclinical studies and submit its Investigational New Drug (IND) application for SPC-15 before year-end, targeting a Phase 1 clinical trial in 2026.
● Strategic Joint Venture (LOI) with Hoth Therapeutics (NASDAQ: HOTH) 50:50 joint venture to develop an anti-obesity and metabolic disease therapy based on VA-patented technology, potentially addressing a $16 billion global obesity market.
● U.S. Patent Office Notice of Allowance Further strengthening IP protection for SPC-15 through a new U.S. patent covering biomarkers for efficacy in stress-induced disorders.
● Device Study Agreement with Resyca BV Partnered with Resyca for a drug-device study validating SPC-15’s proprietary microchip-based intranasal delivery system.
